Wolfe Research cut shares of Fluence Energy (NASDAQ:FLNC – Free Report) from an outperform rating to a peer perform rating in ...

Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...

Investing.com - U.S. President Donald Trump's reciprocal tariff policy is likely to face an elongated implementation timeline ...

CNBC’s Seema Mody and Chris Senyek, Wolfe Research chief investment strategist, join 'Power Lunch' to discuss the Honeywell ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of AnaptysBio (NasdaqGS:ANAB) with a Outperform ...

CVS Health (NYSE:CVS – Free Report) had its target price increased by Wolfe Research from 67.00 to 70.00 in a report ...

The company noted that short-term Bakken headwinds have caused Oneok's stock to lose favor, but the discount is warranted and offers a purchasing opportunity.According to Wolfe, Oneok's recent ...

Wolfe Research Auto, Auto Tech and Semiconductor Conference February 11, 2025 8:45 AM ETCompany ParticipantsJim Farley ...

Wolfe Research Auto, Auto Tech and Semiconductor Conference Call February 12, 2025 12:00 PM ETCompany ParticipantsJohn Wall ...

On Monday, Wolfe Research reiterated a Peerperform rating for Lyft (NASDAQ:LYFT) stock, maintaining a positive outlook as the company approaches its fourth-quarter earnings report set to be ...

Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...